Our top pick for
Cutera, Inc is a medical devices business based in the US. Cutera shares (CUTR) are listed on the NASDAQ and all prices are listed in US Dollars. Cutera employs 323 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$38.38|
|52-week range||$13.73 - $52.61|
|50-day moving average||$47.93|
|200-day moving average||$35.66|
|Wall St. target price||$51.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.49|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||-22.37%|
|3 months (2021-05-05)||30.06%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
Valuing Cutera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cutera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cutera's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 9.05. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cutera's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$165.1 million|
|Gross profit TTM||$75.8 million|
|Return on assets TTM||-3.08%|
|Return on equity TTM||-31.46%|
|Market capitalisation||$910.1 million|
TTM: trailing 12 months
There are currently 1.9 million Cutera shares held short by investors – that's known as Cutera's "short interest". This figure is 1.1% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting Cutera shares can be evaluated.
Cutera's "short interest ratio" (SIR) is the quantity of Cutera shares currently shorted divided by the average quantity of Cutera shares traded daily (recently around 211951.42531357). Cutera's SIR currently stands at 8.77. In other words for every 100,000 Cutera shares traded daily on the market, roughly 8770 shares are currently held short.
However Cutera's short interest can also be evaluated against the total number of Cutera shares, or, against the total number of tradable Cutera shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cutera's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Cutera shares in existence, roughly 100 shares are currently held short) or 0.1227% of the tradable shares (for every 100,000 tradable Cutera shares, roughly 123 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cutera.
Find out more about how you can short Cutera stock.
We're not expecting Cutera to pay a dividend over the next 12 months.
Over the last 12 months, Cutera's shares have ranged in value from as little as $13.73 up to $52.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cutera's is 1.6202. This would suggest that Cutera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cutera, Inc. , a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women's intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars. It also provides excel HR platform, a hair removal solution for various skin types; excel V+, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus, CoolGlide, myQ, and skincare products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website cutera. com.
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.